You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

  • Technology appraisal guidance
  • Reference number: TA537
  • Published:  08 August 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Invitation to participate

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 224 KB)

    Published:
    08 August 2018

Final appraisal determination

  • Final appraisal determination

  • Committee papers (PDF 11.21 MB)

    Published:
    29 June 2018
  • Public committee slides (PDF 714 KB)

    Published:
    29 June 2018
  • Final appraisal determination document (PDF 329 KB)

    Published:
    29 June 2018

Invitation to participate

  • Final scope (PDF 184 KB)

    Published:
    28 November 2017
  • Final matrix (PDF 304 KB)

    Published:
    28 November 2017
  • NICE's response to comments on the draft scope and provisional matrix (PDF 302 KB)

    Published:
    28 November 2017